Evidence map›Paper›PMID 26068396›Full record

ArticleBritish journal of cancer2015

SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma.

P El Hajj, D Gilot, M Migault, A Theunis, L C van Kempen, F Salés, H Fayyad-Kazan, B Badran, D Larsimont, A Awada and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. SMARCA4 promotes benign skin malignant transformation into melanoma through Adherens junction signal transduction.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Article
  11. Article
  12. Article
  13. Effects of microRNAs polymorphism in cancer progression.Medical journal of the Islamic Republic of Iran · 2020
    Review
  14. miRNAs in the Diagnosis and Prognosis of Skin Cancer.Frontiers in cell and developmental biology · 2020
    Review
  15. MicroRNA heterogeneity in melanoma progression.Seminars in cancer biology · 2019
    Review
  16. Article
  17. MicroRNA-155: A Master Regulator of Inflammation.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2019
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

P El HajjLaboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, 1 Rue Heger-Bordet, 1000 Brussels, Belgium.
D GilotCNRS UMR 6290, Université de Rennes 1, 2 Avenue du Pr. Léon Bernard, 35000 Rennes, France.
M MigaultCNRS UMR 6290, Université de Rennes 1, 2 Avenue du Pr. Léon Bernard, 35000 Rennes, France.
A TheunisDepartment of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, 1 Rue Heger-Bordet, 1000 Brussels, Belgium.
L C van KempenDepartment of Pathology, McGill University and Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Chemin de la Côte-Sainte-Catherine, H3T 1E2 Montreal, QC, Canada.
F SalésLaboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, 1 Rue Heger-Bordet, 1000 Brussels, Belgium.
H Fayyad-KazanLaboratory of Experimental Hematology, Institut Jules Bordet, Université Libre de Bruxelles, 1 Rue Heger-Bordet, 1000 Brussels, Belgium.
B BadranDepartment of Biochemistry, Lebanese University, Rafic Campus, 1003 Hadath-Beirut, Lebanon.
D LarsimontDepartment of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, 1 Rue Heger-Bordet, 1000 Brussels, Belgium.
A AwadaClinic of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, 1 Rue Heger-Bordet, 1000 Brussels, Belgium.
L BachelotCNRS UMR 6290, Université de Rennes 1, 2 Avenue du Pr. Léon Bernard, 35000 Rennes, France.
M-D GalibertCNRS UMR 6290, Université de Rennes 1, 2 Avenue du Pr. Léon Bernard, 35000 Rennes, France.
G GhanemLaboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, 1 Rue Heger-Bordet, 1000 Brussels, Belgium.
F JourneLaboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, 1 Rue Heger-Bordet, 1000 Brussels, Belgium.
Université Libre de Bruxelles · BEInstitut Jules Bordet · BEJewish General Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe previously demonstrated an inverse correlation between tyrosinase-related protein 1 (TYRP1) mRNA expression in melanoma metastases and patient survival. However, TYRP1 protein was not detected in half of tissues expressing mRNA and did not correlate with survival. Based on a study reporting that 3' untranslated region (UTR) of TYRP1 mRNA contains two miR-155-5p (named miR-155) binding sites exhibiting single-nucleotide polymorphisms (SNPs) that promote (matched miRNA-mRNA interaction) mRNA decay or not (mismatched), we aimed to investigate the role of miR-155 in the regulation of TYRP1 mRNA expression and protein translation accounting for these SNPs.

methodsThe effect of miR-155 on TYRP1 mRNA/protein expression was evaluated in two melanoma cell lines harbouring matched or mismatched miR-155-TYRP1 mRNA interaction after transfection with pre-miR-155. In parallel, 192 skin and lymph node melanoma metastases were examined for TYRP1 mRNA/protein, miR-155 and SNPs and correlated with patient survival. TYRP1 mRNA, SNPs at its 3'UTR and miR-155 were analysed by RT-qPCR, whereas TYRP1 protein was evaluated by western blot in cell lines and by immunohistochemistry in metastatic tissues.

resultsThe miR-155 induced a dose-dependent TYRP1 mRNA decay and hampered its translation into protein in the line with the 'match' genotype. In melanoma metastases, TYRP1 mRNA inversely correlated with miR-155 expression but not with TYRP1 protein in the 'match' group, whereas it positively correlated with protein but not with miR-155 in the 'mismatch' group. Consequently, in the latter group, TYRP1 protein inversely correlated with survival.

conclusionPolymorphisms in 3'UTR of TYRP1 mRNA can affect TYRP1 mRNA regulation by miR-155 and its subsequent translation into protein. These SNPs can render TYRP1 mRNA and protein expression nonsusceptible to miR-155 activity and disclose a prognostic value for TYRP1 protein in a subgroup of melanoma patients. These data support the interest in the prognostic value of melanogenic markers and propose TYRP1 to refine prognosis in patients with advanced disease.

Indexed as

Polymorphism, Single NucleotideAdultAgedAged, 80 and overBase SequenceCell Line, TumorDNA PrimersFemaleGenotypeHumansMaleMelanomaMembrane GlycoproteinsMicroRNAsMiddle AgedOxidoreductasesDNA PrimersMembrane GlycoproteinsMicroRNAsMIRN155 microRNA, humanOxidoreductasesRNA, MessengerTYRP1 protein, human

Identifiers

PMID26068396
PMCPMC4647532
OpenAlexW1501445218

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.